Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic …
Expanded Role for Immunotherapy to Treat Endometrial Cancer
Apr 12, 2023 · UPDATE: On July 31, 2023, the Food and Drug Administration (FDA) approved dostarlimab (Jemperli) in combination with chemotherapy to treat people with endometrial …
dMMR and Endometrial Cancer | JEMPERLI (dostarlimab-gxly)
Patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer may benefit from an option like JEMPERLI (dostarlimab-gxly) + CP. See full Indication, Safety, & PI.
JEMPERLI - EC Treatment Option for Certain Patients
JEMPERLI is an immunotherapy that may help you fight certain types of advanced or returned endometrial cancer. Discover JEMPERLI, a treatment option. Find information about dosing, …
FDA Approves Immunotherapy for Endometrial Cancer with …
Apr 22, 2021 · Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that …
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
Jul 31, 2023 · With this approval, Jemperli is now indicated earlier in treatment in combination with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial …
FDA D.I.S.C.O. Burst: Jemperli
On February 9, 2023, the FDA approved dostarlimab-gxly (brand name Jemperli) for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as …
Jemperli (dostarlimab) plus chemotherapy approved in the US as ... - GSK
Jul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …
Jemperli: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 7, 2024 · Jemperli (dostarlimab-gxly) is a cancer immunotherapy used to treat types of endometrial cancer and solid tumors. Includes Jemperli side effects, indications, and doses.
FDA Approves Jemperli/Chemo Regimen for Endometrial Cancer …
Jul 31, 2023 · The Food and Drug Administration (FDA) approved Jemperli (dostarlimab) plus carboplatin and paclitaxel followed by Jemperli alone for the treatment of adults with primary …